Use of low-dose XXXX in decreasing cytokine release during bilateral total knee replacement.

@entity1 @entity650 @entity32 @entity649 @entity281 @entity701 @entity230 @entity551 @entity221
BACKGROUND: @entity650 ( @entity650 ), a marker of @entity32 , is one of the major cytokines released during joint replacement. In the orthopedic @entity1 population, high levels have been linked to many adverse effects including acute @entity649 , postoperative mental status changes, and @entity221 . We looked to assess the efficacy of low-dose @entity230 on the postinflammatory response as measured by @entity650 in @entity1 undergoing bilateral total knee replacement (BTKR). The role of @entity230 has never been evaluated before in that setting. METHODS: Double-blind, randomized, placebo-controlled study of 30 @entity1 undergoing BTKR. The study was powered in order to detect at least a 25% decrease in @entity650 from control. @entity701 (100 mg) or placebo was given at 2 doses 8 hrs apart to the study and control group respectively. Clinical outcome was assessed as well. RESULTS: Levels of @entity650 were 40% lower in the study group by 10 hrs (P = 0.0037) but were similar to the control group at 24 hrs. Greater hemodynamic stability was noted in the study group with fewer episodes of @entity551 postoperatively (P = 0.031). Range of motion gained on discharge was also greatest in the study group (P = 0.049). Absence of @entity281 and normal wound healing were noted in all @entity1 . CONCLUSIONS: The use of @entity701 significantly decreased the inflammatory response in @entity1 undergoing BTKR as measured by @entity650 production. Further studies looking at clinical implications of such findings in a larger @entity1 population and with a longer course of @entity230 are warranted.
